The authors especially Observe The shortage of randomized managed trials for orthopaedic indications—which means we will’t confidently say it works, what the real side-impact profile is, or what a “safe dose” will be in the real globe (systematic assessment, 2024).When the aim is “a lot less downtime, more training,” there’s a great d